“…Breast cancer was the first solid cancer from which CSCs were identified and isolated in combination with flowcytometry by Al-Hajj et al (AlHajj et al, 2003;Lindeman and Visvader, 2010). Several studies using the xenograft CSC assay support the CSC model in breast cancer suggesting that ESA+/CD44+/ CD24-/low (Al-Hajj et al, 2003;Wicha et al, 2006) or aldehyde dehydrogenase 1 (ALDH1)+ phenotypes may enrich for breast CSCs which this population may be associated with a poorer prognosis (Balicki, 2007;Ginestier and Wicha, 2007;Lindeman and Visvader, 2010;Madjd et al, 2012).…”